| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | G5A; CK2B; CK2N; CSK2B |
| Entrez GeneID | 1460 |
| clone | 1H8A5 |
| WB Predicted band size | 25kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CSNK2B (AA: FULL(1-215)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及CSNK2B抗体的代表性文献摘要(虚构示例，仅供格式参考)：
---
1. **文献名称**: "CSNK2B regulates cell proliferation via phosphorylation of p53 in breast cancer"
**作者**: Zhang L, et al.
**摘要**: 本研究使用CSNK2B特异性抗体进行免疫沉淀和Western blot分析，发现CSNK2B通过磷酸化p53调控乳腺癌细胞增殖，其高表达与患者预后不良相关。
2. **文献名称**: "The role of CSNK2B in neuronal differentiation and Alzheimer's disease pathology"
**作者**: Kim S, et al.
**摘要**: 通过免疫组化和小鼠模型，发现CSNK2B抗体标记的蛋白在阿尔茨海默病患者脑组织中异常聚集，提示其参与tau蛋白磷酸化及神经元分化障碍。
3. **文献名称**: "Structural insights into CSNK2B interaction with kinase inhibitors"
**作者**: Müller R, et al.
**摘要**: 利用CSNK2B抗体进行共结晶实验，解析了CSNK2B与ATP竞争性抑制剂的结合模式，为开发靶向CK2激酶的抗癌药物提供结构基础。
---
注：以上文献为示例，实际引用需通过PubMed/Google Scholar检索真实文献(关键词：CSNK2B antibody, CK2β, kinase regulation)。如需真实文献，建议补充具体研究背景或应用场景。
The CSNK2B antibody targets the beta subunit of Casein Kinase 2 (CK2), a ubiquitously expressed serine/threonine protein kinase complex. CK2 plays critical roles in cell signaling, proliferation, apoptosis, and DNA repair. The holoenzyme typically consists of two catalytic α/α' subunits (CSNK2A1/A2) and two regulatory β subunits (CSNK2B). The β subunit stabilizes the catalytic subunits, modulates substrate specificity, and influences kinase activity through autophosphorylation or interactions with other proteins.
Antibodies against CSNK2B are widely used in research to study CK2 complex formation, localization, and function. They enable techniques like Western blotting, immunoprecipitation, and immunohistochemistry to investigate CK2's involvement in diseases, including cancer, neurodegenerative disorders, and viral infections, where CK2 dysregulation is often observed.
Commercial CSNK2B antibodies are typically raised against recombinant proteins or synthetic peptides corresponding to conserved regions of the human CSNK2B sequence. Validation includes specificity testing via knockout cell lines or siRNA-mediated knockdown. Researchers must consider potential cross-reactivity with paralogs or splice variants. These tools have advanced understanding of CK2's role in cellular pathways and its potential as a therapeutic target.
×
